Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211406 · ClinicalTrials.gov registry record · Phase 1
Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
A Phase 1 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00211406 is a Phase 1 study that was terminated before completion, run by Manhattan Eye, Ear & Throat Hospital.
The verdict
NCT00211406, a Phase 1 study, was terminated before completion, sponsored by Manhattan Eye, Ear & Throat Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.
Interventions
- DRUG Anecortave Acetate Sterile Suspension (15 mg)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211406
The ClinicalTrials.gov registry entry for NCT00211406 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate Sterile Suspension (15 mg) is the first listed.
NCT00211406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211406 about?
NCT00211406 is a clinical study titled "Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)". The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.
What is the current status of trial NCT00211406?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00211406?
The interventions under investigation include: Anecortave Acetate Sterile Suspension (15 mg) (DRUG).
Who is sponsoring clinical trial NCT00211406?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.